BBHC
MXCT icon

Brown Brothers Harriman & Co’s MaxCyte MXCT Stock Holding History

Brown Brothers Harriman & Co’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,255
Closed -$17.1K – 1600
2025
Q1 		$17.1K Hold
6,255
– – ﹤0.01% 982
2024
Q4 		$26K Hold
6,255
– – ﹤0.01% 980
2024
Q3 		$24.3K Hold
6,255
– – ﹤0.01% 912
2024
Q2 		$24.5K Hold
6,255
– – ﹤0.01% 862
2024
Q1 		$26.2K Hold
6,255
– – ﹤0.01% 858
2023
Q4 		$29.4K Hold
6,255
– – ﹤0.01% 793
2023
Q3 		$19.5K Hold
6,255
– – ﹤0.01% 848
2023
Q2 		$28.7K Hold
6,255
– – ﹤0.01% 793
2023
Q1 		$31K Hold
6,255
– – ﹤0.01% 816
2022
Q4 		$34.2K Hold
6,255
– – ﹤0.01% 785
2022
Q3 		$41K Buy
+6,255
New +$34.9K ﹤0.01% 782

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Brothers Harriman & Co's MXCT Position: Q2 2025 in Review

Brown Brothers Harriman & Co sold out of MaxCyte (MXCT) in Q2 2025, closing a stake of 6,255 shares — an estimated $17.1K sold.

Brown Brothers Harriman & Co first reported a position in MXCT in Q3 2022 and held it in 11 quarters. The position peaked at $41K in Q3 2022. 120 funds tracked by Wall St. Rank hold MXCT as of Q2 2025.

  • Brown Brothers Harriman & Co reported no remaining MaxCyte position as of Q2 2025 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 6,255 MaxCyte shares in Q2 2025, an estimated $17.1K.
  • Brown Brothers Harriman & Co first reported a position in MaxCyte in Q3 2022 and held it in 11 quarters.
  • Brown Brothers Harriman & Co's MaxCyte position peaked at $41K in Q3 2022.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q2 2025.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2025, filed 11 Aug 2025.